#Incretin mimetics

GLP-1, GIP, glucagon receptor agonists.

A Lancet letter raises the maintenance question. SURMOUNT-MAINTAIN supports continued tirzepatide but does not supply an individual dosing formula.

A 25-year semaglutide model weighed cost per QALY against projected equity for older adults with obesity and cardiovascular disease.

A letter on tirzepatide ocular outcomes has no public abstract. The underlying cohort found associations, not proof of eye protection.

A 2026 paper describes reported oral and salivary symptoms with incretin medicines, but it does not establish causation for tirzepatide.

A matched MASLD cohort linked tirzepatide to fewer deaths and liver events than SGLT2 inhibitors, but it cannot prove superiority.

A 2026 review asks why GIP receptor agonists and blockers can both support weight loss, then separates mouse mechanisms from human trial evidence.

What Ozempic and Wegovy labels say about diarrhea, why a symptom report cannot prove causation, and when official guidance calls for assessment.

A 24-week Indian phase 3 trial found Sun Pharma's synthetic semaglutide non-inferior to Wegovy for percentage weight change.

A 2026 meta-analysis found no significant MACE difference versus GLP-1 drugs, with high heterogeneity and mostly observational evidence.

A guide to Wegovy's official adverse-reaction and warning language, and why a forum report cannot diagnose what caused one person's symptoms.

A pooled STEP analysis found more gallbladder events with semaglutide 2.4 mg than placebo, but the absolute event rate remained low.

A 2026 review links obesity treatment with better sleep-apnea measures. We separate its conclusions from the randomized tirzepatide evidence.